

Index

a

- 4,6-acetal 15–20, 123–124, 260–261
 acetalation 260–254
 acetal-protected mannosyl donors 13,
 122–123
 3,4-acetonide 260–261
 acetonitrile 13, 73, 106, 115, 128, 176, 259,
 269, 302–304, 316, 354, 366
 acetylated model 109
 acetylfuran 329, 346, 347
 2-acetylmethyl glycosides, synthesis of 165
 achiral Brønsted acid 158–161, 285
 acid–base catalyzed glycosylation 159
 agelasphines 137, 138
 aglycon 5, 12, 44, 54, 81, 82, 190, 192–194,
 200, 204, 206, 284, 303, 305, 306,
 331, 332, 339, 340, 346
 alginate synthesis, glycosyl sulfonates
 in 126, 127
 alkylidene acetal 39–40, 84–86
 allyl 3,4-di-*O*-benzyl- α -
 L-rhamnopyranoside 304
 allyl ether-mediated intramolecular aglycon
 delivery 84, 85
 allylic azide 346
 allyl α -D-galactofuranoside 304
 armed building blocks 31–35
 α -2-deoxy-2-amino glycosides 168,
 173–206
 $\alpha(2-3)/\alpha(2-6)$ disialyl Lewis A
 heptasaccharide 236
 α 1,3-fucosyltransferase 248
 α -D-galactofuranosides 307, 308, 316
 α -galactoside 82, 256
 α -galactosyl triflate 119
 α -glucosides 99–104, 124–125, 256–258
 α -D-glucoside synthesis, glycosyl sulfonates
 in 124–125
 α -linked GalNAc-Ser/Thr glycosides 177,
 185, 187, 210–204
 $\alpha(2,9)$ -linked sialic acid trimer 234
 α -mannosides 126, 256–257
 α -methyl glucoside 258, 265
 α -methyl glycoside 100, 101
 α -*N*-phenyl trifluoroacetimidate
 donors 20, 117, 130, 189–195
 α 2,9-oligosialic acid preparation 360,
 362
 α -ribofuranosylation 83–84, 305–306,
 313–314
 α S-linked oligosialosides 362, 364
 α -selectivity 10, 45, 67, 69, 71, 99–112,
 124–125, 140, 163–164, 168, 169,
 173–207, 220, 225, 226, 283, 286, 288,
 290–291, 305, 313–314, 354, 363
 α -selective glycosylation reactions 290,
 291, 360
 C4-acyl fucosyl donors 21, 22
 C-sialosides 361
N-acetyl-5-*N*,4-*O*-carbonyl
 thiosialoside 359
N-acetyl-5-*N*,4-*O*-oxazolidinone-
 protected donor 359
 sialylation using 5-*N*,4-*O*-carbonyl
 sialoside 362
 altro-papulacandin 333–334
 aminal-tethered mixed acetal for
 intramolecular aglycon
 delivery 93–94

- 2-amino-2-deoxy- β -D-mannoside synthesis,
glycosyl sulfonates in 123–125
- 1,2-*cis*-2-aminoglycosides
biological importance 173–175
C(2)-*N*-substituted benzylidene glycosyl
trichloroacetimidate
donors 180–187
GPI anchor 197–200
heparin 204
mycothiol 196–197
non-participatory strategy 175–178
nickel-catalyzed 178–180
O-polysaccharides 200
N-phenyl trifluoroacetimidate
donors 180–187
thioglycoside acceptors 190, 194
T_N antigen 201–204
- anchimeric superarming effects 36–38
- 2,3-anhydro-furanose derivatives 119,
121, 307–308
- anhydrosugars 119, 121, 165–166,
268–269, 307–308
- anomeric hemiacetals 45, 116, 177, 287,
290, 291, 293
- anomeric lactones 164–165
- anomeric toluene sulfonates 116,
289–290
- anomeric triflates 119–122, 311
- anthrax tetrasaccharide 345
- anthrose glycosyl donor 346
- apoptolidin A 235
- arabinan 23–24, 87–88, 302
- arabinogalactan heptasaccharide, Boon's
synthesis of 23
- arenesulfonyl triflates 117
- arming participating group 35, 41–44, 48,
104–108
- Au(I)-catalyzed glycosylation
of 1,2-anhydro sugars 166
of glycosyl halides and
trichloroacetimidates 166
Lewis acids 165–166
Yu's studies 66
- Au(III)/phenylacetylene-catalyzed
glycosylation 166–167
- 2-azido-2-deoxyglucopyranosyl
trichloroacetimidate donor 183, 242
- b**
- B3LYP functional DFT calculations 109
- bacterial rare sugars 268–273
- Barton–McCombie deoxygenation 258,
284, 332
- benzenesulfonylpiperidine (BSP)
methods 117
- benzylidene acetals 15, 16, 39, 86–93, 124,
128, 129, 178, 182, 183, 194, 199,
259, 260, 263, 265–267, 364
- benzyl α -D-Galf 300
- β -C(2)-aminoglycosides 175
- β -D-rhamnoside synthesis, glycosyl
sulfonates in 115–116, 123–124
- β -methyl glucoside 258
- β -linked deoxy-sugars 116, 125, 283–287,
289–292
- β -L-rhamnopyranoside (β -L-Rha) 88
- β -mannosylation methodology 15, 17, 19,
82–89, 123, 177
- β -selective electrochemical
glycosylation 73
- β -sialylation 366
- β -thiomannoside 261, 269
- β -zeolites 161
- Boons' chiral auxiliary-based
approach 97–101
- borinate-protected thioglycoside 216, 217
- Breslow intermediate 149–151
- c**
- C-allylations 5, 6, 8, 102, 140
- C(2)-azido
functionality 175
imidate donor 183, 196
- C(2)-oxazolidinone thioglycoside 182, 183
- C6 picolyl (Pico) protecting group 283
- callipeltose donors 332
- callipeltoside C 330–332
- (+)-caprazol 24, 25
- 2-carboxybenzyl (CB) glycoside
donors 305
- cation clock methodology 17, 25, 124
- cationic nickel-catalyzed 1,2-*cis*-2-amino
glycosylation reaction 168,
178–206
- chemical synthesis, of sialosides

- α S-linked oligosialosides 362, 364
- challenges 354
- N-acetyl-5-N,4-O-carbonyl thiosialoside 359
- 5-N,4-O-oxazolidinone 359
- modular sialylated building blocks 361
- chiral Brønsted acids 155–158
- chiral DMAP catalysts 262, 263
- C-glycosides 5, 9, 10, 24, 102, 137, 138, 149, 169
 - C-nucleophiles 9, 10, 24, 141, 145, 147
 - Ferrier-type rearrangement 138–143
 - vs. O-glycosylation reactions 17
 - sigmatropic rearrangement 147–149
 - Tsuji–Trost reaction 145–147
- 1,2-*cis* β -L-arabinofuranosylation 303, 307, 308, 310–313
- 1,2-*cis* β -fructofuranoside 316, 317
- Claisen rearrangement 147–149
- cleistetrosides 244, 325–326, 342–344
- cleistriosides 244, 342–344
- cobalt-catalyzed glycosylation 167–168
- conformationally constrained glycosyl donors 123–125, 163–164, 169, 298, 307–315
- conformationally restricted donors *see* conformationally constrained glycosyl donors
- conformational superarming 35–37, 51
- contact ion pairs (CIPs) 3, 4, 13, 15, 117, 121, 122, 314
- Crich β -mannosylation reaction 15, 16, 30, 117–119, 129, 164, 218, 303, 311
- Cu(OTf)₂ 41, 48, 51, 182, 260, 266, 267, 282
- Curtin–Hammett kinetic scenario 8, 15, 102, 122, 124–125
- 2-cyanobenzyl ether 43–44, 106–108
- 2-cyanoprop-2-yl radicals 226
- cyclic acetals 39, 87, 91 *see also* 4,6-acetal, acetalation
- cyclic ketals 14, 39
- d**
- Danishefsky hetero-Diels–Alder/elimination reaction 328–330
- daumone 339
- D-deoxymannojirimycin 338
- D-arabinofuranosyl thioglycosides 310, 319
- de novo* Achmatowicz approach 336, 338, 340–342, 345, 346
- de novo* oligosaccharide synthesis 249, 282, 285, 298, 342
- 2-deoxy glucopyranosyl acetate 10
- 2-deoxy β -D-glucoside synthesis, glycosyl sulfonates in 125–126, 289–290
- 2-deoxy-glycosyl acetates 286
- bromides and iodides 286, 287
- oxocarbenium ion, in HF/SbF₅ 14
- deoxy-*gulo*-nojirimycin 338
- deoxy-sugars
 - bioactive natural products 279–280
 - Brønsted acid activation of 160
 - glycols 160, 284–285
 - glycosyl halides 285–287
 - oligosaccharide synthesis 279
 - protecting group strategies 283–284
 - reagent controlled approaches 289, 291
 - umpolung reactivity 291
- diarylboronic acids (Ar₂BOH) 248
- diazotransfer method 177, 261
- 1,4-dicyanobenzene (DCNB) 222–223
- 1,4-dicyanonaphthalene (DCN)-photosensitized glycosylation 216, 223
- 2,3-dideoxy donors, disarming effects of 33–34
- dideoxy-D-Swainsonine 340
- dihalocyclopropene/TBAI promoted dehydrative glycosylations 45, 287–288, 290
- dimethylformamide (DMF) modulated disarmed–armed iterative glycosylation 53, 54, 63, 290, 291
- 2,6-dimethylphenyl (DMP) thioglycoside functionality 194
- dimethylsilyl acetal-based intramolecular aglycon delivery approach 82–84
- dimethyltin dichloride catalyzed regioselective esterifications 258, 259
- diorganotin-catalyzed regioselective glycosylations 250
- dioxane, α -directing effect of 69–71

diphenyl sulfoxide (DPSO) methods 117
 donicity number (DN) 60–61
 D-Swainsonine 339–340
 dual catalyzed C-glycosylation 149–151

e

electrochemical glycosylation, solvent
 effects on 73
 electronically superdisarmed building
 blocks 39, 40, 44
 electron-poor alkene acceptor 224–226
 electron transfer photosensitization 213
 electrophilic C-sialylation 361, 363
 electrophilic S-sialylation 361, 363
 energy maps 6, 310
 enzyme-catalyzed regioselective
 glycosylation 246–248
 equatorial glycosyl triflates 17, 118
 Eschenmoser–Claisen
 rearrangement 147, 148
 ether solvent effect
 binary solvent system 70
 for glucosyl tosylates 69
 mechanism 70, 73–74

f

flavan glycoside synthesis 156, 157
 flow chemistry 160
 fluorescence 212
 Fondaparinux 268
 Fraser–Reid's armed–disarmed
 strategy 31–32
 free energy surface (FES) mapping
 method 6–8
 fucosylation reactions 21, 22, 241, 248
 furanose 321, 334
 construction 299–300
 in mammals 297
 stereoelectronic substituent effects 5, 8
 trichloroacetimidate 300–301
 furanoside
 conformationally restricted donors 307
 flexible donors 303–307
 indirect glycosylation 314–318
 oxidation-reduction 318–319
 reactivity tuning 319–321
 1,2-*trans* furanosides 300–303

furanosyl oxocarbenium, conformations
 of 6–8, 309, 310

g

galacto-papulacandins 334–335
 galactono-lactones 334
 Globo H hexasaccharide 52–53
 glucose-derived diazirine 212–213, 238
 glycals 138–151, 160, 284–285
 glycolipids 71, 137, 197–200, 235, 242
 glycosphingolipid 306–307
 armed–disarmed synthesis 46–47
 glycosynthase-catalyzed synthesis 248
 glycosyl 2-pyridyl sulfones, Sm(III) triflate-
 catalyzed glycosylation of 162
 glycosyl halides 62, 166, 285–287 *see also*
 latent glycosyl halides
 glycosyl hydrolases 12, 157, 248
 glycosyl phosphatidyl inositol (GPI)
 anchor 173–174, 197–200
 glycosyl sulfonates
 in alginate synthesis 126–127
 in α -D-glucoside synthesis 124–125
 in 2-amino-2-deoxy- β -D-mannoside
 synthesis 123–125
 in β -rhamnoside synthesis 123–124
 in C-glycosides synthesis 128–129
 C1–O bond 122
 in complex 2-deoxy β -D-glucoside
 synthesis 125–126
 evidence 118–119
 from anomeric hemiacetals 116,
 289–290
 formation 115–118
 in mannan synthesis 123
 in moenomycin pentasaccharide
 synthesis 127
 in polymer-supported oligosaccharides
 synthesis 129–130
 in S-glycosides synthesis 128
 glycosyltransferases 157, 246–248
 glycosyl triflate
 α -configuration 73, 117–119
 applications 123–128
 chemical shift 118–119
 formation and characterization,
 equatorial 17, 118

generation 115–118
 S_N2 -like pathways 119–123
 gold(III)-catalyzed
 pentafuranosylation 301

h

H-bond-mediated aglycone delivery
 (HAD) 44, 283–284, 306–307
 Heck-type C-glycosylation 144–145
 heparin 174–175, 204–206
 heparin disaccharide 176, 177, 204, 206
 hexafluoroisopropanol (HFIP) 215
 homogeneous Brønsted acid
 catalysis 159–160
 Hung's one-pot protection
 strategy 262–266

i

iminosugars 369
 intramolecular aglycon delivery (IAD) 81
 for α -Glc p 88, 92
 benzylidene acetals 86–93
 for β -Araf 88, 91
 for β -D-manno-heptoside 91, 93
 for β -L-Rhap 91, 93
 for β -Man p 87, 89
 dimethoxybenzyl (DMB) ether-
 mediated 86, 88
 dimethylsilyl acetal-based 82–84
 hemiaminal ethers 93
 2-iodoalkylidene acetals 84–86
 ketal type tethers 82
 p-methoxybenzyl (PMB) ether-mediated
 polymer-supported version 87
 propargyl ether-mediated 84, 85
 silicon tethers 82–84
 vinyl ether-mediated 84, 85
 intramolecular hydrogen
 bonding 237–241
 2-iodo- and 2-selenophenylethyl ether
 donors 105–106
 iodonium (di- γ -collidine) perchlorate
 (IDCP) 31, 70–71
 ionic liquid-catalyzed one-pot reactivity
 based glycosylation 162–163
 ionic liquids (ILs) 71–73, 159
 Ireland–Claisen rearrangement 148

Ir-photosensitized glycosylation 215

j

Jacobsen catalyst 328–330

k

Kahne glycosylation 107, 127
 KDO-sugar derivative 328–329
 Koenigs–Knorr glycosylation 59, 62, 249

l

landomycin A hexasaccharide 279–280,
 283
 landomycin E trisaccharide 281, 341–342
 L-arabinofuranosyl thioglycosides 302–
 303, 310–311, 316, 319–321
 latent glycosyl halides 287–289
 Leloir-type glycosyltransferases 246
 Lemieux's azidonitration
 method 176–177
 Lewis basicity index 60
 L-fucofuranosylation 305
 lincomycin analogues 128
 lipoarabinomannan (LAM) 297, 303, 306,
 314–317
 littoralisone 330–331

m

mannuronic acids 17–20, 118, 126–127
 merremoside D 346–347
 metalloglycosylidenes 224
 metals, Lewis acids
 anomeric allylation, of xyloxy
 fluorides 169
 α -glycosylations 163, 164
 conformationally constraint glycosyl
 donors 163
 O-glycoside synthesis 161
 α -S-sialoside formation 164
 cobalt 167–168
 gold 165–167
 iron 168
 nickel 168, 182
 stereoselective lactonization 164, 165
 mezzettiasides 342, 343
 Mizoroki–Heck reaction *see* Heck-type
 glycosylation
 molecular dynamics simulations 73–74

monosaccharide natural products 337–341
 mucin antigens *see* T_N antigen
 Mukaiyama type *anti*-aldol reaction 331
 mycobacterial arabinan *see* arabinan
 mycothiol (MSH) 175, 189, 196–199

n

2-*N*-acetamido sugar mimics 165
 natural occurring C-glycosides 137, 138
 neighbouring group participation (NGP)
 C-2 ether functions 67, 302
 O-2 achiral auxiliary 103–106
 O-2 chiral auxiliary 97–103
 1,2-*trans* glycosides synthesis 97–98
 neuraminic acids *see* sialic acids
N-heterocyclic carbene (NHC)-catalyzed C-glycosylations 149
N-iodosuccinimide (NIS) 31, 67, 82, 234, 290, 359
N-linked glycans 71, 84–87, 175, 247–248
N-methylquinolinium hexafluorophosphate (NMQ-PF₆) sensitizer 218–219
 nitrile solvent effect, on glycosylation 64–69
 nitrosyl tetrafluoroborate (NOBF₄) 161–162, 359
N,N'-bis[3,5-bis-(trifluoromethyl)phenyl]thiourea 160
 5-*N*,4-*O*-oxazolidinone-protected phosphate donor 362
 5-*N*,7-*O*-oxazinanone protected sialyl donor, glycosylation of 364, 365
N-phenyl trifluoroacetimidates donors 179–180, 187–206
 nucleoside glycosylation 160

o

O-aryl glycosides 214, 220–223, 340–341
 phenylglucoside donors 216
 O'Doherty iterative dihydroxylation approach 334–335
 one-pot glycosylation reaction 21–22, 48–49, 51, 53–54, 60, 161–163, 291, 302, 319, 359–360
 6-*O*-pentafluorobenzoyl (PFBz) group 38–39, 50

2-*O*-picolinyl group 35, 41–42, 44, 48, 50
 orthogonally protected D-galactosamine thioglycoside building blocks 269–271
ortho-nitrobenzyl arming participating groups 43
 3,5-*O*-tetra-*i*-propylidisiloxanyllidene (3,5-*O*-TIPDS) protecting groups 311–313
O-triflates 268–273
 oxathiane ether donors 108–111
 oxocarbenium ions 5, 12–14, 21–24, 32, 43, 61, 62, 74, 97, 99, 100, 102, 103, 106, 108, 110, 119, 121–123, 308–311
 arming and disarming protecting groups 122
 DFT calculations 10, 11, 25
 generation in continuous-flow microreactor 5
 Koenigs–Knorr-type glycosylation 59
 lifetime in aqueous solution 4
 NMR spectroscopy 14–15
 reactivity and conformational behavior 5–10
 stability 4–10
 Koenigs–Knorr-type glycosylation 59
 mannuronic acid 19, 20
 nitrile solvent 64
 NMR spectroscopy 14–15
 S_N1-type pathways 3
 stability, reactivity and conformational behavior of 4–10
 2,3-*O*-xylylene arabinofuranosyl thioglycoside 314, 315

p

papulacandin ring system 328–330, 333–334, 337–338
 Pd-catalyzed decarboxylative C-glycosylation 146–147
 phenanthrene-photosensitized pyranilation/glycosylation 221–223
 phenylselenoglycoside 217–221
 phenylthiolglycoside 194, 195, 216, 217
 photochemical glycosylation 211
 chalcogenoglycoside donors 214–223

- glycosyl trichloroacetimidates 223–224
 nitrene insertion 224, 225
 organic photoacids 223
 photochemical flow reactors 211
 photochemistry basics 212–213
 photosensitized
 C-glycosylation 224–228
 photosensitizers 212, 213, 219, 221–223, 226, 227
 PhSePh-promoted photochemical glycosylation 220–221
 polyols
 regioselective protection 256–262
 trimethylsilyl protection 262–268
 potassium alkynyltrifluoroborates 140
 preactivation glycosylation strategy 17, 48, 52–54, 128, 163–164, 287–288, 290–291, 313–314, 359
p-toluenesulfonic anhydride 289–290
p-toluenesulfonyl-4-nitroimidazole 289–290
- q**
 quantum mechanical calculation
 method 4, 6–8, 10–14, 74, 99
- r**
 reactivity levels, armed *vs.* disarmed
 building blocks 33–34
 reagent/catalyst controlled
 glycosylations 155–158, 289–291
 regioselective benzylation 258
 regioselective glycosylation methods
 enzyme-catalyzed 246–248
 glycosyl acceptors 234–238
 glycosyl donor/acceptor
 matching 241–243
 protective groups 239–241
 reagent-controlled 243–246
 synthetic catalysts 248–250
 regioselective O4 acylation 262–263
 relative reactivity values (RRVs) 5, 34, 359–361
 rhamnogalacturonan II 311
 RSK inhibitor SL0101 synthesis 340–341
 Ru(bpy)₃(PF₆)₂ photosensitizer 219–221, 226
- s**
 S-benzoxazolyl (SBox) glycosyl donors,
 superarming of 36–37
 Schreiner's thiourea 160
 selenoglycosides 217–220
 SEt glycosyl donors, superarming
 of 36–37
 sialic acids 353–354
 sialyl phosphate fragmentation, onset cone
 voltages of 362, 364
 silyllallene nucleophiles 140
 simplified Jablonski diagram 212, 213
 singlet excited state 212
 S_N2-type mechanism 3–4, 9–10, 15–17, 20, 45, 64, 99, 109–110, 119–125, 157, 159, 241, 244, 249–250, 281, 286–291
 solvent effects, on glycosylation 59
 dissolution function 60
 ionic liquids 71–73
 molecular dynamics
 simulations 73–74
 polar and coordinating
 solvents 64–68
 polar and noncoordinating
 solvents 62–63
 weakly polar and coordinating
 solvents 68–71
 weakly polar and noncoordinating
 solvents 63–64
 stereoelectronic substituent effects 8, 15, 102, 122, 309, 313, 319
 stereoselectivity 139
 Stetter reaction 149–150
 Stoddart's hemisphere representation 12
- t**
 tandem Tebbe methylenation–Claisen
 rearrangement 148–149
 Tebbe's reagent 82, 83, 148–149
 tetrazole-based Brønsted acid ionic
 liquids 159
 T_N antigen 201–204
 1,2-*trans*-aminoglycosides 175
trans-directing 2-O-picolinylated armed
 glycosyl donors 50
 1,2-*trans* furanosides 300–303

- trichloroacetimidate donor 65, 72, 98–99, 101, 105, 158–163, 166–169, 179–190, 192, 202, 223, 236, 238, 240, 242–243, 283, 301–304, 311, 313–314
- Bronsted-acid-catalyzed glycosylation 157, 158
- nitrile solvent effect 65
- photoacid-promoted approach 223, 224
- (salen)Co-catalyzed glycosylation of 167, 168
- trimethylsilyl (TMS)-glycoside 262–268, 331
- triphenylphosphine oxide (TPPO) 305, 306
- 2,4,6-triphenylpyrylium-photosensitized glycosylation 219, 220
- Trypanosoma cruzi* mucin 300, 301
- tumor-associated carbohydrate antigens (TACAs) 175, 201 *see also* T_N antigen
- u**
- umpolung reactivity 149–150, 291–293
- unimolecular S_N1 mechanism 29
- v**
- vinylfuran 335–337
- Vorbrüggen glycosylation 160
- w**
- Williamson conditions 103, 104
- Woerpel's model 5–6, 8–10, 101–102, 308
- z**
- ZnCl₂-catalyzed glycosylation, of per-O-pivaloylated glycosides 161, 162

